Blog

  • AI–Enhanced SALT Score Improves Accuracy in Alopecia Areata Assessment

    AI–Enhanced SALT Score Improves Accuracy in Alopecia Areata Assessment

    A novel artificial intelligence (AI) tool could improve the accuracy and objectivity of alopecia areata severity and treatment efficacy, according to the authors of a proof-of-concept case report published in JAAD Case Reports.1

    The current standard for quantifying hair loss in alopecia areata is the Severity of Alopecia Tool (SALT) score, the authors explained. But in real-world clinical practice, the SALT score is rarely used due to its time-consuming nature and, notably, high interrater variability.2 Trichoscopy is another tool that allows for more detailed visualization of the hair and scalp to differentiate alopecia areata and monitor treatment progress, but it has limited availability in clinical settings because it requires specialized equipment and examiner expertise.

    The new approach detailed in the care report leverages an AI-powered assessment tool to track and manage alopecia areata.1 The system automatically calculates the area of alopecia (AI-Area) to derive an AI-SALT score.

    “This case demonstrates a proof-of-concept for tracking and managing [alopecia areata] using an AI-based assessment tool,” the authors wrote. “For this case of [alopecia areata], AI is used to calculate accurate areas of alopecia, and trichoscopy was used to detect early follicular regrowth, providing a faster, more comprehensive, and objective evaluation of disease progression and treatment response.”

    In the case of a 47-year-old male receiving intralesional triamcinolone acetonide for a solitary alopecia areata patch, the AI tool provided a more accurate and sensitive assessment than traditional manual methods. Specifically, the AI-SALT Score captured incremental progress between early visits that the Manual-SALT Score failed to detect.

    “Using the AI tool to assess this patient’s alopecia, demonstrates fast, easy-to-use AI-powered imaging via smartphone to precisely and objectively quantify alopecia for clinical evaluation,” the authors wrote. “Furthermore, percentage change of alopecia area provides more accurate and sensitive assessment than the manual SALT system demonstrated by the AI-SALT scores’ finer decimal-level precision.”

    This enhanced sensitivity has a direct impact on patient adherence and overall management value. At the 8-week mark, the patient was considering discontinuing treatment due to a lack of noticeable improvement based on subjective observation. However, the AI tool’s objective data, which demonstrated clear progress, alongside trichoscopic images showing hair regrowth, motivated the patient to continue therapy. This demonstrates the tool’s ability to ensure sustained adherence when therapy is working and improve outcomes.

    A crucial aspect of the case is that it shows the AI tool’s capacity to generate objective, standardized documentation, the authors noted. Insurers routinely require precise evidence of disease severity, including accurate SALT scores, to approve high-cost treatment coverage. By offering fast, easy-to-use, and highly precise quantification, this AI-based system can provide the verifiable metrics needed to satisfy coverage requirements, potentially reducing administrative burden and accelerating patient access to care.

    “Today, AI tools are increasingly being used to assess skin disorders, and we are beginning to integrate these tools into our daily clinical practice,” the authors explained. “In this case, the integration of AI enabled more accurate monitoring and patient engagement, suggesting potential to improve care through personalized and informed management of [alopecia areata].”

    The tool does have limitations, they noted, especially in cases of androgenetic alopecia, which does not have distinct patches of hair thinning. However, combining AI assessment with trichoscopy to quantify individual hairs or follicular units does enhance assessment, they explained. The AI-SALT score’s utility should also be validated in more severe or widespread alopecia and beyond single-patch cases, as well as in diverse populations.

    “Here, we present a proof-of-concept for integrating AI tools in clinical settings to assess and monitor AA, demonstrating the potential to deliver precise and objective data that inform treatment decisions and patient engagement,” the authors concluded. “However, this is a proof-of-concept used on one patient, and further validation is necessary to ensure broader applicability.”

    References

    1. Chan E, Ramsay K, Tyli R, et al. AI-based alopecia assessment: a proof of concept for enhancing accuracy and objectivity in hair loss measurement. JAAD Case Rep. Published online October 7, 2025. doi:10.1016/j.jdcr.2025.09.023.

    2. King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther. 2022;12(4):825-834. doi:10.1007/s13555-022-00711-3

    Continue Reading

  • MaxSun’s wild new liquid-cooled dual GPU card packs 48GB of memory and might just bend workstation logic to its will

    MaxSun’s wild new liquid-cooled dual GPU card packs 48GB of memory and might just bend workstation logic to its will


    • MaxSun design revives long-abandoned dual-GPU engineering with modern cooling
    • Each slim card manages 48GB of memory and dual GPUs in tight spaces
    • MaxSun Intel Arc Pro B60 48G Turbo Edition allows dense GPU stacking across full PCIe 5.0 bandwidth

    Continue Reading

  • AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients

    AstraZeneca today announces a historic agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation.

    At a landmark event at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the Company voluntarily met all requests set out in the President’s July 31st letter. The Company agrees to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.

    As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

    AstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America. This will be achieved through the Company’s recently announced $50 billion investment in US medicines manufacturing and R&D over the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which is expected to be generated in the US.

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”

    AstraZeneca’s commitment to the US and American patients is further reflected in the Company’s largest single investment in a manufacturing facility to date, where the Company broke ground yesterday in Virginia. This facility will support AstraZeneca’s weight management and metabolic portfolio and our leading antibody drug conjugate cancer pipeline. Additionally, a newly expanded manufacturing facility in Coppell, Texas, will officially open next week. Looking ahead, AstraZeneca will open a cell therapy manufacturing facility in Rockville, Maryland early next year and its second major R&D centre in Cambridge, Massachusetts will open in late 2026.

    The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company’s US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.

    Notes

    AstraZeneca’s agreement with US Government
    This is the second agreement that a pharmaceutical company has made with the US Department of Health and Human Services to lower the cost of medicines for American patients in the past two weeks. Specific terms of this agreement remain confidential.

    AstraZeneca

    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on social media @AstraZeneca.

    Media Inquiries

       Fiona Cookson               

    +1 (212) 814-3923

    US Media Mailbox: usmediateam@astrazeneca.com           

    Continue Reading

  • Live updates: 19 missing after huge blast at Tennessee explosives plant

    Live updates: 19 missing after huge blast at Tennessee explosives plant

    Raw materials usually to blame when things with explosives go wrong – ballistics expertpublished at 21:16 BST

    Freya Scott-Turner
    Live reporter

    Usually when things go wrong with explosives, it’s with the
    raw materials says Dr Chris…

    Continue Reading

  • US moves to cancel one of the world’s largest solar farms

    US moves to cancel one of the world’s largest solar farms

    Unlock the White House Watch newsletter for free

    The US has moved to cancel what would have been the largest solar project in North America, as the Trump administration expands its attack on the embattled renewable energy industry.

    Late on Thursday the Bureau of Land Management scrapped approval for Esmeralda 7, a 6.2 gigawatt project that could have powered nearly 2mn homes. It had begun the permitting process under the Biden administration.

    The high-profile Nevada solar project backed by NextEra Energy, the largest renewable energy company in the US, is the latest to become a casualty of the Trump administration. The American president has called renewable energy projects a “scam”.

    The Esmeralda 7 project consisted of seven solar farms and battery systems and was backed by power developers including Arevia Power, ConnectGen and Invenergy. It would have covered about 62,300 acres of federal lands in the Nevada desert north-west of Las Vegas.

    Since January, Doug Burgum’s Department of the Interior has accelerated permitting for fossil fuel projects while tightening restrictions on solar and wind initiatives.

    Large offshore wind projects have already been drawn into the administration’s crosshairs. In April Burgum ordered Equinor to halt construction activities on its 810 megawatt Empire offshore wind farm and issued a stop work order on Ørsted’s Revolution Wind.

    While both projects were eventually allowed to proceed, industry backers say the uncertainty undermines US energy needs and investor confidence.

    The crackdown on renewables comes as the country faces soaring power demand due to the proliferation of data centres to fuel the rise of artificial intelligence as well as the electrification of vehicles and home appliances.

    NV Energy, the state’s largest utility, projects that power demand will be 34 per cent higher in 2035 compared with 2022.

    “We remain deeply concerned that this administration continues to flout the law to the detriment of consumers, the grid and America’s economic competitiveness,” said Ben Norris, vice-president of regulatory affairs for the Solar Energy Industries Association.

    “We need more power on the grid, fast, and the solar and storage industry is ready to provide it, but we need the administration to get serious about truly achieving American energy dominance.” 

    The Department of the Interior did not confirm that the project had been cancelled, but said it and the project developers had “agreed to change” approach and that they would have the option to “submit individual project proposals to . . . more effectively analyse potential impacts”.

    NextEra said it “remain[s] committed to pursuing our project’s comprehensive environmental analysis by working closely with the Bureau of Land Management”.

    Invenergy declined to comment.

    Continue Reading

  • Honor’s new teaser details the Magic8 Pro’s telephoto camera

    Honor’s new teaser details the Magic8 Pro’s telephoto camera

    Honor has released some new teasers about its upcoming Magic8 Pro, and specifically about its 200 MP telephoto camera. This will have a 1/1.4″ type sensor, the AIMAGE Honor Nox Engine, a large f/2.6 aperture, and, according to the brand,…

    Continue Reading

  • Gymnastics governing body reacts to Indonesia’s worlds block on Israel team | Athletics News

    Gymnastics governing body reacts to Indonesia’s worlds block on Israel team | Athletics News

    Indonesia has denied visas to Israel athletes ahead of the upcoming world championships in the world’s most populous Muslim-majority nation.

    Gymnastics’ governing…

    Continue Reading

  • Frequent Dining Out Linked to Higher Colorectal Cancer Risk

    Frequent Dining Out Linked to Higher Colorectal Cancer Risk

    Regularly eating meals away from home may carry more than just financial costs. A large cohort study of over 42,000 adults in China found that frequent dining out was significantly associated with an increased risk of colorectal cancer.1 The…

    Continue Reading

  • Photos of October's supermoon: A stunning start to a trio of celestial events – Chronicle-Tribune

    Photos of October's supermoon: A stunning start to a trio of celestial events – Chronicle-Tribune

    1. Photos of October’s supermoon: A stunning start to a trio of celestial events  Chronicle-Tribune
    2. The Hunter’s Moon is back and it’s a supermoon: Here’s what to know  ABC News – Breaking News, Latest News and Videos
    3. Spectacular sight for harvest…

    Continue Reading

  • Europe’s Interoperability Push Undermines Western Tech Leadership

    Europe’s Interoperability Push Undermines Western Tech Leadership

    Many successful tech firms rely on closed, integrated ecosystems that limit third-party access to preserve consistent performance, user privacy, and device security. With its Digital Markets Act, the European Commission has mandated a different approach by requiring a small number of designated “gatekeepers,” the vast majority of which are American, to open up their platforms to third parties. But the EU’s interoperability requirements do not just create heavy engineering burdens on firms and distort investment into new features, they also directly harm European consumers by forcing companies like Apple to weaken its security and withhold innovative new features in the single market.

    The DMA imposes numerous interoperability obligations on service providers, which the EU has framed as necessary to ensure “all developers have an effective and predictable path to interoperability and are enabled to innovate.” Notably, Article 6(7) sets out specific obligations for ensuring “effective interoperability”—a tenuous standard in practice which, as ITIF has argued, is not limited to protecting as-efficient competitors and the EU is enforcing in a way akin to public utility regulation rather than more “light touch” conduct-focused rules. In addition to interoperability, the DMA’s Article 6(4) also requires gatekeepers to allow sideloading applications and Article 5(4) bans gatekeepers from restricting business users from steering customers to other platforms or payment options.

    The EU’s DMA interoperability regime is already imposing a heavy cost. Specifically, the DMA’s interoperability rules broadly require Apple to give third-party developers the same level of access to core iOS software features that Apple’s own apps and services enjoy. As such, Apple is being forced to gut the seamless and secure ecosystem that it has built and optimized internally for years. Not only does this increase the number of external developers with deep system access to iOS, creating privacy and security risks, but it also reduces Apple’s incentive and ability to roll out new features. Indeed, the introduction of Apple Intelligence, the company’s new suite of on-device AI tools, was already delayed in Europe, signaling a new normal in which European consumers may receive major technological innovations later than the rest of the world.

    The interoperability provisions also reach into Apple’s hardware ecosystem, posing yet another set of important risks to security and privacy that will be passed on to consumers in the form of reduced innovation. For example, the European Commission’s interoperability rules for connected devices limit Apple’s ability to roll out new features without having to effectively white-label them for third-party connected device rivals. Unsurprisingly, this has had a chilling effect on Apple’s European release of Live Translation for AirPods, a new feature that synchronizes audio between the earbuds and the iPhone in real time. Delivering Live Translation to third-party earbuds requires opening low-level audio and pairing controls that currently keep user data secure, and doing so risks compromising conversation data. Unfortunately, the new normal for European consumers is clear: delayed or stifled innovation for reduced privacy and security.

    In addition to the interoperability requirements, the EU is using other parts of the DMA to tear down Apple’s “walled garden.” For example, anti-steering provisions require Apple to allow developers to direct users to external payment channels, bypassing the App Store’s vetted transaction system—dismantling the secure payment architecture that has long protected users from fraud and unauthorized data collection. Moreover, sideloading rules force Apple to permit alternative app stores and direct app downloads outside its established review process. As Apple has pointed out, this change has not only created a more fragmented user experience, but enabled the distribution of apps that circumvent local laws, such as gambling applications in jurisdictions where gambling is illegal. Rather than protect consumers, the DMA is introducing new vectors for fraud and illegal content.

    To be sure, this undermining of American tech companies under the DMA is no accident; EU policymakers deliberately calibrated the DMA’s gatekeeper thresholds to capture leading American tech companies while exempting European competitors (only later was one European company, Booking.com, designated). Indeed, DMA rapporteur Andreas Schwab expressly stated that the regulation should focus on the “top five” rather than include European firms to “appease the United States.” This discriminatory approach underscores how the EU is using digital regulations like the DMA for protectionist economic reasons rather than to promote consumer welfare.

    Indeed, the DMA’s interoperability mandates are discriminatory in both design and effect. For American gatekeepers, these obligations impose steep compliance costs, force the disclosure of proprietary technology, and delay product rollouts. This undermines not only U.S. but broader Western technological leadership because it creates opportunities primarily for Chinese rivals to free ride off the DMA and close the global technological gap. The Trump administration has made clear it will not tolerate such measures, and with good reason: when regulations target U.S. companies, they cease to be neutral competition policy and become non-tariff trade barriers. If Brussels continues down this path, the result will be not only weaker Western competitiveness but also escalating transatlantic trade frictions—damaging EU-U.S. relations while the United States reconsiders its trade policies.

    The DMA’s current approach is not a balanced competition policy, but rather a set of overbroad, discriminatory mandates that impose disproportionate burdens on American firms, weaken Western technological leadership, and risk deepening trade frictions at a moment when transatlantic cooperation is crucial. Promoting competition and expanding opportunities for developers are worthwhile goals, but they should be pursued through collaborative frameworks that provide the utmost respect for privacy, security, and technical feasibility, rather than be imposed through heavy-handed regulations like the DMA. Otherwise, the EU’s course risks undermining not just innovation, but also the collective ability of the West to maintain its technological edge against strategic rivals such as China.

    Continue Reading